Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS
penetration rates and have shown favorable response rates in brain metastases. Brain
radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic
metastases, however, the role of local treatment especially in driver mutation-positive
non-small cell lung cancer with asymptomatic brain metastases is being questioned given their
potential side effects. No randomized trial has shown the superiority of early vs delayed
cranial RT in asymptomatic BM of driver mutated NSCLC.